ROIV - Roivant Sciences Ltd logo

Roivant Sciences Ltd

ROIV

Roivant Sciences Ltd. develops and commercializes medicines and technologies, focusing on clinical-stage biopharmaceuticals. Its candidates include monoclonal antibodies for autoimmune diseases and small molecule inhibitors for immune-mediated conditions.

βš•οΈ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago β†’$5,366today

Score Overview

1 Year
Score
Net Growth11.18%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth-8.81%
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Score4.3
Net Growth68.50%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth-86.38%
Rev Trend20%
Revenue Consistencyβ€”
All Time
Score
Net Growth68.50%
Net Trend40%
Net Income Consistency
Rev Growth-86.38%
Rev Trend20%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Roivant Sciences Ltd has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ROIV does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 36.49β€”
1 Year2025-10-23
$ 18.12101.38%
5 Years2021-10-22
$ 6.80436.62%
All Time2021-10-01
$ 9.35290.27%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 7M-$ 266M$ 3.84B
2026$ 8M-$ 299M$ 4.29B
2025$ 29M-$ 171M$ 4.88B
2024$ 32M$ 4.34B$ 6.54B
2023$ 31M-$ 1.00B$ 1.68B
2022$ 55M-$ 845M$ 2.06B
ROIV - Roivant Sciences Ltd logo

Roivant Sciences Ltd fundamental performance

Between 2022 and 2026, revenue declined from $ 55M to $ 8M and net income went from -$ 845M to -$ 299M. Revenue increased in 20% of the years measured; net income in 40%.

Roivant Sciences Ltd currently holds a 5-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.

Membership

Explore ROIV with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies